RegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidanceRegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidance
International Education

Advancing the Science of
Cannabinoid Medicine

International professional education covering cannabinoid science, clinical practice, evidence, and regulatory frameworks — for healthcare professionals, researchers and policy leaders worldwide.

Evidence-led
Curriculum grounded in peer-reviewed science
International
Educators drawn from multiple continents
Academically led
Curriculum directed by our Director of Education
The Institute provides education only. It does not provide medical advice or supply medicinal cannabis products.
About the Institute

An independent international academy for cannabinoid medicine.

The Institute for Cannabinoid Therapy is an independent international educational organisation bringing together clinicians, scientists and regulatory experts from multiple jurisdictions. Together, they build a rigorous, evidence-based curriculum that advances the safe and responsible practice of cannabinoid therapeutics.

International
Educators drawn from across the continents.
Academically led
Curriculum set by our academic leadership, not by any product interest.
Evidence-based
Grounded in current science and clinical trial data.
Practitioner-first
Built for the clinical and regulatory realities of practice.
Why Study Cannabinoid Medicine

A rapidly evolving field that demands rigour.

Neuron and receptor illustration
  • 01
    Rapid scientific development

    The evidence base for cannabinoid therapeutics is expanding at unprecedented pace.

  • 02
    Increasing clinical interest

    Patients and colleagues are asking informed questions in every specialty.

  • 03
    Changing international regulation

    Regulatory landscapes are shifting across most major jurisdictions.

  • 04
    Evidence-based education

    Rigorous appraisal is essential to separate signal from noise.

  • 05
    Patient safety first

    Understanding benefits, limitations, contraindications and interactions.

Learning Pathway

A structured route from foundations to focused clinical depth.

View all courses
Step 01 · Foundations

Foundation Course in Cannabinoid Therapy

The Institute's flagship programme: twelve modules spanning cannabinoid science, safety, clinical applications and prescribing, taught by international clinicians and researchers.

  • Endocannabinoid System
  • Medicinal Cannabis
  • Pharmacology
  • Clinical Applications
  • Prescribing
Program
USD $500
Enrol
Step 02 · Individual Modules

Individual specialised modules

Focused, self-paced modules across pharmacology, cannabinoids and clinical indications.

  • An Overview of Anxiety and Medicinal Cannabis
  • An Overview of Chronic Pain and Medicinal Cannabis
  • An Overview of Medicinal Cannabis
  • An Overview of Pharmacokinetics, Pharmacodynamics and Safety of Cannabis
  • An Overview of Sleep Disorders and Medicinal Cannabis
  • Brain Cancer and Medicinal Cannabis
  • + five further modules
Per module
USD $100
Browse
Regulation by Jurisdiction

Individual modules on regulation, jurisdiction by jurisdiction.

Short, purchasable modules comparing prescribing frameworks, product access and practitioner responsibilities in a single jurisdiction — released progressively as each is written and reviewed.

View jurisdictions
Australia
United States
Canada
United Kingdom
Germany
Italy
Switzerland
New Zealand
South America

Jurisdiction modules are released progressively. Register your interest to be notified as each becomes available.

These reviews are educational only and do not constitute legal advice. Regulations change frequently. Practitioners remain responsible for understanding and complying with local laws applicable to their jurisdiction and scope of practice.

Educators

Led by Professor Kylie O'Brien, Director of Education.

Our teaching is directed by Professor Kylie O'Brien — academic, clinical researcher and author of three Springer titles. Further educators are being confirmed and added as each joins the teaching team.

Multi-continental Published authors Active researchers Dedicated educators
Meet our educators
Academic leadership

Every module is shaped by academic leadership and clinical experience — spanning ECS biology, clinical pharmacology, pain, mental health, women's health and regulatory science.

Begin

Ready to advance your practice in cannabinoid medicine?

Enrol in the Foundation Course (USD $500) or purchase individual modules (USD $100 each), including focused modules on regulation in your jurisdiction.